Five Prime Therapeutics, Inc. stock price
Today's NASDAQ:FPRX chart, history & news
Price:
15.37
USD
Change:
+1.15 (8.09%)
Key stats
| Price open | 14.6 |
|---|---|
| Previous close | 14.22 |
| Market cap | 584.64M |
| Volume | 0.92M |
| Day high | |
| Day low | |
| Year high | 22.43 |
| Year low | 1.86 |
| Year to date change | -1.55% |
| P/E ratio | N.A |
Company Profile
Fundamentals
Insider Information
News
Company information
Company name
Five Prime Therapeutics, Inc.
Exchange
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Thomas Civik
Address
111 Oyster Point Blvd, South san francisco, California, 94080-1910
Country
United States
Contact information
14153655600
Website
http://www.fiveprime.com/
Related companies
Five Prime Therapeutics, Inc. earnings reports (2020)
| Q2 2020 | Q1 2020 | Q1 2020 | |
|---|---|---|---|
| Actual EPS | -0.48 | -0.57 | -0.57 |
| Consensus EPS | -0.69 | -0.67 | -0.67 |
| Announce Time | AMC | AMC | AMC |
| Number of Estimates | 7 | 8 | 8 |
| EPS Surprise Dollar | 0.21 | 0.1 | 0.1 |
| EPS Report Date | 06-08-2020 | 06-05-2020 | 06-05-2020 |
| Fiscal End Date | 30-06-2020 | 30-03-2020 | 30-03-2020 |
| Year Ago | -0.99 | -1.02 | -1.02 |
| Year Ago % Change | 51.52% | 44.12% | 44.12% |
Five Prime Therapeutics, Inc. earnings reports (2019)
| Q4 2019 | Q3 2019 | Q2 2019 | |
|---|---|---|---|
| Actual EPS | -0.89 | -1.03 | -0.99 |
| Consensus EPS | -0.97 | -0.95 | -0.9 |
| Announce Time | AMC | AMC | AMC |
| Number of Estimates | 9 | 10 | 10 |
| EPS Surprise Dollar | 0.08 | -0.08 | -0.09 |
| EPS Report Date | 27-02-2020 | 06-11-2019 | 06-08-2019 |
| Fiscal End Date | 31-12-2019 | 29-09-2019 | 29-06-2019 |
| Year Ago | -1.12 | -1.37 | -0.99 |
| Year Ago % Change | 20.54% | 24.82% | 0% |
Five Prime Therapeutics, Inc. income statements (2020) (USD)
| June 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|
| Total Revenue | N.A | N.A | N.A | N.A |
| Cost of Revenue | N.A | N.A | N.A | N.A |
| Gross Profit | N.A | N.A | N.A | N.A |
| Research & Development | 6.84M | 6.84M | 16.28M | 16.28M |
| Selling General & Admin | 7.59M | 7.59M | 10.47M | 10.47M |
| Operating Expense | N.A | N.A | N.A | N.A |
| Operating Income | -12.37M | -12.37M | -19.63M | -19.63M |
| Other Income Expense Net | -4.56M | -4.56M | -487K | -487K |
| EBIT | -12.37M | -12.37M | -19.63M | -19.63M |
| Interest Income | N.A | N.A | N.A | N.A |
| Pretax Income | -16.94M | -16.94M | -20.12M | -20.12M |
| Income Tax | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -16.94M | -16.94M | -20.12M | -20.12M |
| Net Income Basic | -16.94M | -16.94M | -20.12M | -20.12M |
Five Prime Therapeutics, Inc. income statements (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Total Revenue | N.A | N.A | 3.33M | N.A |
| Cost of Revenue | N.A | N.A | 1.33M | N.A |
| Gross Profit | N.A | N.A | 2M | N.A |
| Research & Development | 20.06M | 25.76M | 28.09M | 28.62M |
| Selling General & Admin | 8.36M | 13.21M | 9.66M | 10.51M |
| Operating Expense | N.A | N.A | 39.09M | N.A |
| Operating Income | -27.28M | -37.17M | -35.75M | -35.12M |
| Other Income Expense Net | -4.07M | 1.10M | 1.36M | -269K |
| EBIT | -27.28M | -37.17M | -35.75M | -35.12M |
| Interest Income | N.A | N.A | N.A | N.A |
| Pretax Income | -31.36M | -36.07M | -34.39M | -35.39M |
| Income Tax | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -31.36M | -36.07M | -34.39M | -35.39M |
| Net Income Basic | -31.36M | -36.07M | -34.39M | -35.39M |
Five Prime Therapeutics, Inc. income statements (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Total Revenue | N.A | 5.77M | 7.58M | 32.49M |
| Cost of Revenue | N.A | 1.27M | 1.31M | 1.15M |
| Gross Profit | N.A | 4.50M | 6.28M | 31.34M |
| Research & Development | 33.44M | 43.41M | 32.08M | 42.40M |
| Selling General & Admin | 9.58M | 9.83M | 9.78M | 10.48M |
| Operating Expense | N.A | 54.52M | 43.16M | 54.03M |
| Operating Income | -40.28M | -48.75M | -35.58M | -21.54M |
| Other Income Expense Net | 1.53M | 1.50M | 1.52M | 1.15M |
| EBIT | -40.28M | -48.75M | -35.58M | -21.54M |
| Interest Income | N.A | N.A | N.A | N.A |
| Pretax Income | -38.75M | -47.24M | -34.06M | -20.39M |
| Income Tax | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -38.75M | -47.24M | -34.06M | -20.39M |
| Net Income Basic | -38.75M | -47.24M | -34.06M | -20.39M |
Five Prime Therapeutics, Inc. income statements (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Total Revenue | N.A | 8.33M | 7.82M |
| Cost of Revenue | N.A | 619K | 597K |
| Gross Profit | N.A | 7.71M | 7.23M |
| Research & Development | 31.89M | 42.11M | 41.15M |
| Selling General & Admin | 10.48M | 9.67M | 9.36M |
| Operating Expense | N.A | 52.41M | 51.11M |
| Operating Income | -29.93M | -44.07M | -43.29M |
| Other Income Expense Net | 721K | 792K | 702K |
| EBIT | -29.93M | -44.07M | -43.29M |
| Interest Income | N.A | N.A | N.A |
| Pretax Income | -29.21M | -43.28M | -42.58M |
| Income Tax | N.A | N.A | 1.70M |
| Minority Interest | 0 | 0 | 0 |
| Net Income | -29.21M | -43.28M | -44.29M |
| Net Income Basic | -29.21M | -43.28M | -44.29M |
Five Prime Therapeutics, Inc. balance sheet (2020) (USD)
| June 2020 | March 2020 | March 2020 | |
|---|---|---|---|
| Current Cash | 58.71M | 67.69M | 67.69M |
| Receivables | 2.21M | 2.17M | 2.17M |
| Inventory | N.A | N.A | N.A |
| Current Assets | 134.45M | 150.29M | 150.29M |
| Other Current Assets | 5.18M | 7M | 7M |
| Short Term Investments | 68.35M | 73.44M | 73.44M |
| Long Term Investments | 1.54M | 1.54M | 1.54M |
| Property/Plant Equipment | 46.67M | 48.58M | 48.58M |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A |
| Tangible Assets (Net) | 119.94M | 134.54M | 134.54M |
| Other Assets | 2.68M | 2.56M | 2.56M |
| Total Assets | 185.35M | 202.97M | 202.97M |
| Accounts Payable | 346K | 767K | 767K |
| Other Current Liabilities | 15.26M | 14.23M | 14.23M |
| Total Current Liabilities | 20.01M | 19.21M | 19.21M |
| Total Liabilities | 65.40M | 68.43M | 68.43M |
| Long Term Debt | 43.20M | 44.41M | 44.41M |
| Current Long Term Debt | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 |
| Common Stock | 35.48M | 35.32M | 35.32M |
| Treasury Stock | N.A | N.A | N.A |
| Retained Earnings | -468.94M | -452M | -452M |
| Capital Surplus | 588.82M | 586.45M | 586.45M |
| Shareholder Equity | 119.94M | 134.54M | 134.54M |
| Other Liabilities | N.A | N.A | N.A |
Five Prime Therapeutics, Inc. balance sheet (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Current Cash | 55.80M | 48.93M | 38.31M | 29.63M |
| Receivables | 4.10M | 3.66M | 2.60M | 3.36M |
| Inventory | N.A | N.A | N.A | N.A |
| Current Assets | 166.72M | 197.49M | 230.02M | 250.54M |
| Other Current Assets | 6.24M | 7.84M | 13.28M | 10.22M |
| Short Term Investments | 100.58M | 137.05M | 175.83M | 207.33M |
| Long Term Investments | 1.54M | 1.54M | 1.54M | 1.54M |
| Property/Plant Equipment | 53.47M | 57.31M | 59.17M | 60.87M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A | N.A |
| Tangible Assets (Net) | 150.47M | 178.43M | 206.61M | 234.33M |
| Other Assets | 2.41M | 2.20M | 2.18M | 2.81M |
| Total Assets | 224.14M | 258.54M | 292.91M | 315.76M |
| Accounts Payable | 2.27M | 4.23M | 3.52M | 4.44M |
| Other Current Liabilities | 16.67M | 20.33M | 26.15M | 15.94M |
| Total Current Liabilities | 23.02M | 28.51M | 33.50M | 24.07M |
| Total Liabilities | 73.67M | 80.11M | 86.30M | 81.44M |
| Long Term Debt | 45.53M | 46.57M | 47.60M | 48.60M |
| Current Long Term Debt | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 35.22M | 35.10M | 34.96M | 34.84M |
| Treasury Stock | N.A | N.A | N.A | N.A |
| Retained Earnings | -431.88M | -400.53M | -364.46M | -330.07M |
| Capital Surplus | 582.24M | 578.85M | 570.89M | 564.32M |
| Shareholder Equity | 150.47M | 178.43M | 206.61M | 234.33M |
| Other Liabilities | N.A | N.A | N.A | N.A |
Five Prime Therapeutics, Inc. balance sheet (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Current Cash | 43.95M | 64.05M | 52.79M | 65.94M |
| Receivables | 5.10M | 5.02M | 2.71M | 4.27M |
| Inventory | N.A | N.A | N.A | N.A |
| Current Assets | 288.57M | 332.86M | 363.02M | 403.04M |
| Other Current Assets | 13.33M | 6.25M | 7.54M | 9.35M |
| Short Term Investments | 226.19M | 257.55M | 299.98M | 323.49M |
| Long Term Investments | 1.54M | 1.54M | 1.54M | 1.54M |
| Property/Plant Equipment | 28.72M | 29.28M | 30.03M | 30.29M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A | N.A |
| Tangible Assets (Net) | 265.14M | 296.78M | 336.86M | 362.22M |
| Other Assets | 2.71M | 2.69M | 2.19M | 1.84M |
| Total Assets | 321.53M | 366.36M | 396.78M | 436.71M |
| Accounts Payable | 5.35M | 2.50M | 2.47M | 1.83M |
| Other Current Liabilities | 22.13M | 37.02M | 27.76M | 39.34M |
| Total Current Liabilities | 27.49M | 39.52M | 30.22M | 41.17M |
| Total Liabilities | 56.40M | 69.59M | 59.92M | 74.50M |
| Long Term Debt | N.A | N.A | N.A | N.A |
| Current Long Term Debt | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 34.75M | 34.53M | 34.45M | 34.33M |
| Treasury Stock | N.A | N.A | N.A | N.A |
| Retained Earnings | -294.68M | -255.93M | -208.68M | -174.62M |
| Capital Surplus | 559.89M | 552.92M | 545.89M | 537.39M |
| Shareholder Equity | 265.14M | 296.78M | 336.86M | 362.22M |
| Other Liabilities | N.A | N.A | N.A | N.A |
Five Prime Therapeutics, Inc. balance sheet (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Current Cash | 59.79M | 36.45M | 59.71M |
| Receivables | 13.13M | 4.36M | 3.83M |
| Inventory | N.A | N.A | N.A |
| Current Assets | 311.19M | 333.35M | 363.30M |
| Other Current Assets | 5.37M | 8.24M | 8.75M |
| Short Term Investments | 232.90M | 284.31M | 291.01M |
| Long Term Investments | 1.54M | 1.54M | 1.54M |
| Property/Plant Equipment | 30.76M | 22.50M | 15.23M |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A |
| Tangible Assets (Net) | 265.20M | 286.09M | 323.27M |
| Other Assets | 552K | 23K | 37K |
| Total Assets | 344.05M | 357.42M | 380.11M |
| Accounts Payable | 6.23M | 2.89M | 1.32M |
| Other Current Liabilities | 44.75M | 42.83M | 34.25M |
| Total Current Liabilities | 50.98M | 45.72M | 35.57M |
| Total Liabilities | 78.85M | 71.33M | 56.84M |
| Long Term Debt | N.A | N.A | N.A |
| Current Long Term Debt | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 |
| Common Stock | 28.18M | 28.07M | 27.99M |
| Treasury Stock | N.A | N.A | N.A |
| Retained Earnings | -155.61M | -126.4M | -83.11M |
| Capital Surplus | 421.26M | 412.68M | 406.66M |
| Shareholder Equity | 265.20M | 286.09M | 323.27M |
| Other Liabilities | N.A | N.A | N.A |
Five Prime Therapeutics, Inc. cash flow (2020) (USD)
| June 2020 | March 2020 | |
|---|---|---|
| Net Income | -16.94M | -20.12M |
| Depreciation | 1.99M | 1.29M |
| Changes in Receivables | -46K | 1.93M |
| Changes in Inventories | N.A | N.A |
| Cash Change | -8.98M | 11.89M |
| Cash Flow | -19.96M | -14.09M |
| Capital Expenditures | N.A | -29K |
| Investments | 5.08M | 27.27M |
| Investing Activity (other) | N.A | N.A |
| Total Investing Cash Flows | 11.81M | 27.24M |
| Dividends Paid | N.A | N.A |
| Net Borrowings | -1.03M | -0.99M |
| Other Financing Cash Flows | N.A | N.A |
| Cash Flow Financing | -835K | -1.26M |
| Exchange Rate Effect | N.A | N.A |
Five Prime Therapeutics, Inc. cash flow (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Net Income | -31.36M | -36.07M | -34.39M | -35.39M |
| Depreciation | 3.81M | 1.19M | 1.33M | 1.33M |
| Changes in Receivables | -433K | -1.06M | 761K | 1.73M |
| Changes in Inventories | N.A | N.A | N.A | N.A |
| Cash Change | 6.87M | 10.63M | 8.67M | -14.32M |
| Cash Flow | -28.71M | -27M | -22.57M | -32.68M |
| Capital Expenditures | -198K | 58K | -653K | -0.98M |
| Investments | 36.71M | 39.19M | 32.27M | 19.79M |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | 36.51M | 39.25M | 31.62M | 18.80M |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | -0.91M | -0.92M | -1.08M | N.A |
| Other Financing Cash Flows | N.A | N.A | N.A | N.A |
| Cash Flow Financing | -0.93M | -1.62M | -371K | -448K |
| Exchange Rate Effect | N.A | N.A | N.A | N.A |
Five Prime Therapeutics, Inc. cash flow (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Net Income | -38.75M | -47.24M | -34.06M | -20.39M |
| Depreciation | 1.29M | 1.27M | 1.31M | 1.15M |
| Changes in Receivables | -81K | -2.3M | 1.56M | 8.86M |
| Changes in Inventories | N.A | N.A | N.A | N.A |
| Cash Change | -20.09M | 11.26M | -13.16M | 6.15M |
| Cash Flow | -52.58M | -30.93M | -28.38M | -10.62M |
| Capital Expenditures | -184K | -414K | -9.89M | -840K |
| Investments | 32.28M | 43.20M | 24.06M | -90.71M |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | 32.09M | 42.79M | 14.17M | -91.55M |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | N.A | N.A | N.A | N.A |
| Other Financing Cash Flows | N.A | N.A | N.A | N.A |
| Cash Flow Financing | 392K | -597K | 1.06M | 108.32M |
| Exchange Rate Effect | N.A | N.A | N.A | N.A |
Five Prime Therapeutics, Inc. cash flow (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Net Income | -29.21M | -43.28M | -44.29M |
| Depreciation | 782K | 619K | 597K |
| Changes in Receivables | -8.78M | -524K | 2.08M |
| Changes in Inventories | N.A | N.A | N.A |
| Cash Change | 23.34M | -23.26M | 12.53M |
| Cash Flow | -27.46M | -27.7M | -29.09M |
| Capital Expenditures | -1.31M | -1.05M | -757K |
| Investments | 51M | 6.54M | 41.55M |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | 49.69M | 5.49M | 40.80M |
| Dividends Paid | N.A | N.A | N.A |
| Net Borrowings | N.A | N.A | N.A |
| Other Financing Cash Flows | N.A | N.A | N.A |
| Cash Flow Financing | 1.12M | -1.05M | 809K |
| Exchange Rate Effect | N.A | N.A | N.A |
Five Prime Therapeutics, Inc. dividends (USD)
Insider Roster
| Entity name | Report date | Shares held |
|---|---|---|
| Biotechnology Value Trading Fund OS LP | 13-11-2020 | 81,263 |
| LAMPERT MARK N | 13-11-2020 | 81,263 |
| BIOTECHNOLOGY VALUE FUND II LP | 13-11-2020 | 81,263 |
| BVF Partners OS Ltd. | 13-11-2020 | 81,263 |
| BVF PARTNERS L P/IL | 13-11-2020 | 81,263 |
| BVF INC/IL | 13-11-2020 | 81,263 |
| BVF II GP LLC | 13-11-2020 | 81,263 |
| BVF I GP LLC | 13-11-2020 | 81,263 |
| BVF GP HOLDINGS LLC | 13-11-2020 | 81,263 |
| Civik Thomas | 14-04-2020 | 480,000 |
Insider Summary
| Full name | Reported title | Total bought | Total sold | Net transacted |
|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 5,709,152 | 14,786,680 | -9,077,528 |
Insider Transactions
| Full name | Reported title | Effective date | Amount of shares | Price per share | Total cost |
|---|---|---|---|---|---|
| BVF INC/IL | 06-10-2020 | +162,352 | 5.04 | +817,442.00 | |
| White David | Vice President, Finance and Principal Accounting Officer | 30-09-2020 | -6,916 | 4.70 | 32,505.20 |
| BIOTECHNOLOGY VALUE FUND L P | 22-09-2020 | +32 | 3.80 | +121.56 | |
| Collins Helen Louise | EVP and Chief Medical Officer | 20-08-2020 | -827 | 4.69 | 3,878.63 |
| Nicholson Garry A | 14-05-2020 | +20,000 | N.A | N.A | |
| BVF INC/IL | 14-05-2020 | +4,476 | 4.10 | +18,351.60 | |
| RINGO WILLIAM R | 19-04-2020 | +78,408 | N.A | N.A | |
| Civik Thomas | President and CEO | 13-04-2020 | +480,000 | N.A | N.A |
| William R. Ringo | Interim CEO; Director | 19-12-2019 | +49,552 | N.A | N.A |
| 09-12-2019 | +113,874 | 4.02 | +457,773.48 | ||
| 09-12-2019 | +18,729 | 4.02 | +75,290.58 | ||
| 09-12-2019 | +2,397 | 4.02 | +9,635.94 | ||
| Franklin M. Berger | Director | 03-12-2019 | -47,890 | 4.00 | 191,560.00 |
| Franklin M. Berger | Director | 02-12-2019 | -32,090 | 3.92 | 125,792.80 |
| David V. Smith | Executive Vice President & CFO | 26-11-2019 | -6,611 | 3.77 | 24,923.47 |
| 22-11-2019 | +81,857 | 3.40 | +278,313.80 | ||
| 22-11-2019 | +462,056 | 3.40 | +1,570,990.40 | ||
| 22-11-2019 | +576,097 | 3.40 | +1,958,729.80 | ||
| William R. Ringo | Interim CEO; Director | 19-11-2019 | +50,367 | N.A | N.A |
| 05-11-2019 | +496,721 | 4.00 | +1,986,884.00 | ||
| 05-11-2019 | +70,921 | 4.00 | +283,684.00 | ||
| 05-11-2019 | +400,470 | 4.00 | +1,601,880.00 | ||
| 31-10-2019 | +504 | 3.85 | +1,940.40 | ||
| 31-10-2019 | +2,913 | 3.85 | +11,215.05 | ||
| 31-10-2019 | +3,416 | 3.85 | +13,151.60 | ||
| 30-10-2019 | +1,456 | 3.89 | +5,663.84 | ||
| 30-10-2019 | +8,236 | 3.89 | +32,038.04 | ||
| 30-10-2019 | +10,389 | 3.89 | +40,413.21 | ||
| 29-10-2019 | +240 | 3.90 | +936.00 | ||
| 29-10-2019 | +1,133 | 3.90 | +4,418.70 | ||
| 29-10-2019 | +1,027 | 3.90 | +4,005.30 | ||
| 25-10-2019 | +2,155 | 3.75 | +8,081.25 | ||
| 25-10-2019 | +12,899 | 3.75 | +48,371.25 | ||
| 25-10-2019 | +15,728 | 3.75 | +58,980.00 | ||
| 24-10-2019 | +1,629 | 3.74 | +6,092.46 | ||
| 24-10-2019 | +57,723 | 3.74 | +215,884.02 | ||
| 24-10-2019 | +76,036 | 3.74 | +284,374.64 | ||
| 23-10-2019 | +3,200 | 3.75 | +12,000.00 | ||
| William R. Ringo | Interim CEO; Director | 19-10-2019 | +46,939 | N.A | N.A |
| 08-10-2019 | +4,689 | 3.68 | +17,255.52 | ||
| 08-10-2019 | +24,716 | 3.68 | +90,954.88 | ||
| 08-10-2019 | +31,007 | 3.68 | +114,105.76 | ||
| 07-10-2019 | +24,425 | 3.75 | +91,593.75 | ||
| 07-10-2019 | +14,242 | 3.75 | +53,407.50 | ||
| 07-10-2019 | +138,609 | 3.75 | +519,783.75 | ||
| 07-10-2019 | +80,821 | 3.75 | +303,078.75 | ||
| 07-10-2019 | +168,640 | 3.75 | +632,400.00 | ||
| 07-10-2019 | +98,333 | 3.75 | +368,748.75 | ||
| William R. Ringo | Interim CEO; Director | 05-10-2019 | +34,451 | N.A | N.A |
| 04-10-2019 | +991 | 3.74 | +3,706.34 | ||
| 04-10-2019 | +7,314 | 3.74 | +27,354.36 | ||
| 04-10-2019 | +7,695 | 3.74 | +28,779.30 | ||
| Helen Collins | EVP and Chief Medical Officer | 01-09-2019 | -496 | 5.43 | 2,693.28 |
| President & CEO; Director | 01-09-2019 | -3,306 | 5.43 | 17,951.58 | |
| Lewis T. Williams | Director | 01-09-2019 | -7,024 | 5.43 | 38,140.32 |
| Francis Willard Sarena | Chief Strategy Officer | 01-09-2019 | -2,811 | 5.43 | 15,263.73 |
| Francis Willard Sarena | Chief Strategy Officer | 01-09-2019 | -2,811 | 5.43 | 15,263.73 |
| Lewis T. Williams | Director | 01-09-2019 | -7,024 | 5.43 | 38,140.32 |
| President & CEO; Director | 01-09-2019 | -3,306 | 5.43 | 17,951.58 | |
| Helen Collins | EVP and Chief Medical Officer | 01-09-2019 | -496 | 5.43 | 2,693.28 |
| Helen Collins | EVP and Chief Medical Officer | 20-08-2019 | +5,000 | N.A | N.A |
| Helen Collins | EVP and Chief Medical Officer | 20-08-2019 | +20,000 | N.A | N.A |
| David V. Smith | Executive Vice President & CFO | 24-06-2019 | +44,000 | N.A | N.A |
| Helen Collins | SVP and Chief Medical Officer | 24-06-2019 | +44,000 | N.A | N.A |
| President & CEO; Director | 24-06-2019 | +124,420 | N.A | N.A | |
| Francis Willard Sarena | Chief Strategy Officer | 24-06-2019 | +44,000 | N.A | N.A |
| Lori Lyons-Williams | Director | 23-06-2019 | +25,000 | N.A | N.A |
| Garry Allen Nicholson | Director | 10-06-2019 | +15,000 | N.A | N.A |
| Kapil Dhingra | Director | 10-06-2019 | +15,000 | N.A | N.A |
| Peder K. Jensen | Director | 10-06-2019 | +15,000 | N.A | N.A |
| William R. Ringo | Director | 10-06-2019 | +15,000 | N.A | N.A |
| Lewis T. Williams | Director | 10-06-2019 | +15,000 | N.A | N.A |
| Franklin M. Berger | Director | 10-06-2019 | +15,000 | N.A | N.A |
| Carol A. Schafer | Director | 10-06-2019 | +1,250 | N.A | N.A |
| President & CEO; Director | 07-06-2019 | -11,357 | N.A | N.A | |
| President & CEO; Director | 07-06-2019 | +11,357 | 5.54 | +62,917.78 |